Methylenetetrahydrofolate reductase gene polymorphisms:: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

被引：66

作者：

Marcuello, E

Altés, A

Menoyo, A

Del Rio, E

Baiget, M

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Genet, Barcelona 08025, Spain

[2] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona 08025, Spain

[3] Hosp Esperit Sant, Dept Hematol, Barcelona 08923, Spain

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2006年 / 57卷 / 06期

关键词：

colon cancer; fluoropyrimidines; methylenetetrahydrofolate reductase; pharmacogenetics;

D O I：

10.1007/s00280-005-0089-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) may play a central role in the action of 5-FU, an inhibitor of thymidylate synthase, by converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. The aim of this study was to ascertain whether two polymorphisms in the MTHFR gene (677C > T and 1298 A > C) could be used as genomic predictors of clinical response to fluoropyrimidine-based chemotherapy (in combination with irinotecan or oxaliplatin). Ninety-four patients diagnosed with metastatic colorectal cancer and undergoing 5-FU-containing chemotherapy as a first line treatment were studied. The results suggest that the MTHFR genotype cannot be considered as an independent factor of outcome in colorectal cancer patients under 5-FU-based chemotherapy.

引用

页码：835 / 840

页数：6

共 19 条

[11]

Martínez-Frías ML, 2004, MED CLIN-BARCELONA, V122, P361

[12] A SIMPLE SALTING OUT PROCEDURE FOR EXTRACTING DNA FROM HUMAN NUCLEATED CELLS [J].

MILLER, SA ;

DYKES, DD ;

POLESKY, HF .

NUCLEIC ACIDS RESEARCH, 1988, 16 (03) :1215-1215

[13]

Revilla JIG, 2003, MED CLIN-BARCELONA, V120, P441, DOI 10.1157/13045517

[14] Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines [J].

Sekhon, J ;

Pereira, P ;

Sabbaghian, N ;

Schievella, AR ;

Rozen, R .

BRITISH JOURNAL OF CANCER, 2002, 87 (02) :225-230

[15] Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate [J].

Sohn, KJ ;

Croxford, R ;

Yates, Z ;

Lucock, M ;

Kim, YI .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (02) :134-144

[16] Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo [J].

Stankova, A ;

Shang, JJ ;

Rozen, R .

CLINICAL CANCER RESEARCH, 2005, 11 (05) :2047-2052

[17] A second common mutation in the methylenetetrahydrofolate reductase gene:: An additional risk factor for neural-tube defects? [J].

van der Put, NMJ ;

Gabreëls, F ;

Stevens, EMB ;

Smeitink, JAM ;

Trijbels, FJM ;

Eskes, TKAB ;

van den Heuvel, LP ;

Blom, HJ .

AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (05) :1044-1051

[18]

*WHO, 1979, PUBL WHO, V48

[19] Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR):: findings from over 7000 newborns from 16 areas world wide [J].

Wilcken, B ;

Bamforth, F ;

Li, Z ;

Zhu, H ;

Ritvanen, A ;

Redlund, M ;

Stoll, C ;

Alembik, Y ;

Dott, B ;

Czeizel, AE ;

Gelman-Kohan, Z ;

Scarano, G ;

Bianca, S ;

Ettore, G ;

Tenconi, R ;

Bellato, S ;

Scala, I ;

Mutchinick, OM ;

López, MA ;

de Walle, H ;

Hofstra, R ;

Joutchenko, L ;

Kavteladze, L ;

Bermejo, E ;

Martínez-Frías, ML ;

Gallagher, M ;

Erickson, JD ;

Vollset, SE ;

Mastroiacovo, P ;

Andria, G ;

Botto, LD .

JOURNAL OF MEDICAL GENETICS, 2003, 40 (08) :619-625

← 1 2 →